Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades
Journal of Cancer · 2025-07-24 · 16 (11) · 3425-3449
DOI: 10.7150/jca.108163 ↗At a glance
Übersichtsarbeit in Journal of Cancer, published on 2025-07-24. Written by Dinglin Liu and 6 co-authors. Institution: Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, China. Cited 17 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
In recent years, immune checkpoint blockades (ICBs) have made rapid progress in the field of cancer treatment, providing significant therapeutic effects and survival benefits, especially in patients with advanced refractory tumors. PD-1/PD-L1 blockade is one of the most widely used ICBs. However, its application is limited by low response rate and drug resistance. It is of great significance to investigate the complex mechanisms of PD-1/PD-L1 blockade resistance. In this review, we outline some crucial aspects, including lack of effector T cells, lack of target PD-1/PD-L1, poor immunogenicity of tumors, immunosuppressive TME, and other mechanisms (such as metabolism, epigenetic alterations, and gut microbiota). Combination therapy has become a promising strategy to overcome drug resistance. Based on the upregulation of other immune checkpoints after PD-1/PD-L1 blockade treatment, we focus on the combination with other ICBs, including CTLA-4, TIM-3, LAG-3, TIGIT, VISTA, and some emerging immune checkpoints, so as to provide evidence for improving the benefit of ICBs in cancers.
Subjects
Author keywords
Authors and institutions
- Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, China.
- Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze University, 1 Nanhuan Road, Jingzhou, Hubei 434023, China.
Cite
APA
Liu, D., Xiao, H., Xiang, Y., Zhong, D., Liu, Y., Wang, Y., & Zhang, W. (2025). Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades. Journal of Cancer, 16(11), 3425-3449. https://doi.org/10.7150/jca.108163
Vancouver
Liu D, Xiao H, Xiang Y, Zhong D, Liu Y, Wang Y, et al. Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades. Journal of Cancer. 2025;16(11):3425-3449. doi:10.7150/jca.108163
BibTeX
@article{Liu2025,
author = {Liu, Dinglin and Xiao, Haoyue and Xiang, Ying and Zhong, Dian and Liu, Yuchen and Wang, Yunfei and Zhang, Weijia},
title = {Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades},
journal = {Journal of Cancer},
year = {2025},
volume = {16},
number = {11},
pages = {3425--3449},
doi = {10.7150/jca.108163}
}
EUVIMED